Astrocytoma III

Anaplastic Astrocytoma

Anaplastic astrocytoma are classified as malignant glioma. With high propability they are a progression from an astrocytoma grade II, but they can also be newly diagnosed.

Histology of Anaplastoc Astrocytoma

  • fast growing, diffusely infiltrating tumour (WHO III)

 

Epidemology of Anaplastic Astrocytoma

  • peak age between 40 and 60
  • also in childhood (frequently as ponsglioma)
  • twice as often in men

 

Symptoms of Anaplastic Astrocytoma

  • similar to tumours with WHO-grade II
  • epileptic seizures
  • signs of intracranial pressure (headache, nausea and emesis, fatigue
  • psychological disorders (changes in personality)
  • neurological deficits (sensory disturbances, paralysis, speech disorders)

 

Diagnosing Diffuse Astrocytoma

  • MRI, CT and biopsy
  • heterogenous contrast-enhancement (especially in tumour margin)
  • tend to edema formation
  • frequently margins to normal tissue are not identifiable
  • nfiltrated tissue seems swollen
  • main localisation: cerebrum (frontal- and temporal lobe, basal ganglia)

 

Therapy of Anaplastic Astrocytoma

  • complete as possible surgical removal
  • in inoperable tumours: biopsy for diagnosis backup
  • radiotherapy on tumour volume and safety margin of 2 cm
  • chemotherapy

 

Therapy in Recurrent Anaplastic Astrocytoma

  • re-operation
  • second irradiation
  • chemotherapy, possibly with different chemotherapeutic agent
  • experimental treatments

 

Aftercare of Anaplastic Astrocytoma

  • first imaging 6 weeks after therapy
  • subsequently MRI every three months

 

Course of Anaplastic Astrocytoma

  • not rarely they transform to higher-grade tumour (glioblastoma)

 

Prognosis of Anaplastic Astrocytoma

  • despite treatment worse prognosis

Wissenswertes

Tumortherapiefelder

Lebensqualität und Behandlung mit elektrischen Wechselfeldern

> read more

PCV beim Gliom Grad 2

Alleinige Chemotherapie wirksam

> read more

Cannabinoide beim Glioblastom

Erste Studiendaten zu Nabiximols und TMZ

> read more